At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

CSL Ltd (ASX: CSL) shares have fallen around 0.5% in Wednesday morning trade, to $198.92 at the time of writing.

Despite this morning's decrease, the shares have now rebounded 116% since hitting a 10-year low in June this year.

The ASX biotech shares are now up around 16% year-to-date and 10% higher than 12 months ago.

There has been a huge rebound in investor confidence in CSL shares over the past couple of months, driven by an impressive FY26 result, news of a new exclusive deal, and the appointment of a new CEO. 

It looks like the company is finally turning a corner. But now the question is, at around the $199 mark, are CSL shares still a bargain, or a risky investment?

Let's take a look.

A woman looks nonplussed as she holds up a handful of Australian $50 notes.

Image source: Getty Images

The business has huge market scale

CSL has an incredibly dominant position in a high-growth global biotechnology market. As a company that develops and delivers biotherapies and vaccines to support people with life-threatening medical conditions, its products are in high demand.

The company has three major divisions. CSL's Behring is a major powerhouse in the global plasma market. Its Seqirus business is the world's second-largest influenza vaccine manufacturer. And CSL Vifor is a global leader in therapies for iron deficiency and iron deficiency anaemia.

There is also likely to be an ongoing need for immunoglobulin, influenza vaccines, and plasma therapies, and CSL is well-placed to scoop up a lot of that demand.

It's returning to growth… slowly

CSL suffered a shaky 18-month period to mid-2026, but plans to undertake aggressive cost-saving measures and a restructure have helped create a turnaround in earnings in FY26.

In FY26, the company delivered US$176 million in pre-tax savings, which was well ahead of schedule. It also reported total revenue of US$15.8 billion and underlying NPAT of US$3.1 billion for FY26 in mid-August. 

Management described FY26 as a 'reset year' for CSL and said it expects FY27 to be the year the company returns to growth, with guidance of a 5% increase in underlying NPAT.

Guidance signals an operational turnaround and bottom line recovery for CSL. But a 5% NPAT increase suggests a slow return to growth, rather than an aggressive one.

It makes me question: is CSL's ability to generate growth and profit now reliant on its aggressive cost-cutting plan, or true business expansion?

Headwinds are still there

The huge operational headwinds the company has faced this year, including higher costs, logistics and shipping issues, and softer US vaccine demand, aren't likely to abate in the near term.

Brokers think CSL shares are fully priced

Analysts are mostly positive on the biotech shares going forward. But after such a huge rebound from the June low, it looks like they've reached around fair value.

TradingView data shows the majority of analysts (10 out of 19) still maintain a buy/strong buy rating. Another eight rate CSL shares as a hold, and one has a sell rating.

The average $200.57 target price implies the shares only have a small potential upside of around 1% at the time of writing. 

Are CSL shares a bargain or a risk at $199? Here's my verdict

CSL has undergone an impressive operational turnaround this year. But after such a strong share price rally over the past five months, I think CSL shares could be risky.

The shares are no longer trading at a bargain price. I'm also concerned that the latest rally assumes CSL's growth plans will unfold without issues.

The risk is that any setback could significantly derail confidence and send the share price crashing.

Until I see further evidence that CSL's cost efficiency and growth plans are trickling through to its balance sheet, I'm sitting tight for now.

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »